Abstract
Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have